MYT1 role in the microtia-craniofacial microsomia spectrum.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
10 2020
Historique:
received: 09 06 2020
accepted: 23 06 2020
pubmed: 2 9 2020
medline: 1 6 2021
entrez: 2 9 2020
Statut: ppublish

Résumé

Craniofacial microsomia (CFM), also known as the oculo-auriculo-vertebral spectrum, comprises a variable phenotype with the most common features including microtia and mandibular hypoplasia on one or both sides, in addition to lateral oral clefts, epibulbar dermoids, cardiac, vertebral, and renal abnormalities. The etiology of CFM is largely unknown. The MYT1 gene has been reported as a candidate based in mutations found in three unrelated individuals. Additional patients with mutations in this gene are required to establish its causality. We present two individuals with CFM that have rare variants in MYT1 contributing to better understand the genotype and phenotype associated with mutations in this gene. We conducted genetic analysis using whole-exome and -genome sequencing in 128 trios with CFM. Two novel MYT1 mutations were identified in two participants. Sanger sequencing was used to confirm these mutations. We identified two additional individuals with CFM who carry rare variants in MYT1, further supporting the presumptive role of this gene in the CFM spectrum.

Sections du résumé

BACKGROUND
Craniofacial microsomia (CFM), also known as the oculo-auriculo-vertebral spectrum, comprises a variable phenotype with the most common features including microtia and mandibular hypoplasia on one or both sides, in addition to lateral oral clefts, epibulbar dermoids, cardiac, vertebral, and renal abnormalities. The etiology of CFM is largely unknown. The MYT1 gene has been reported as a candidate based in mutations found in three unrelated individuals. Additional patients with mutations in this gene are required to establish its causality. We present two individuals with CFM that have rare variants in MYT1 contributing to better understand the genotype and phenotype associated with mutations in this gene.
METHODS/RESULTS
We conducted genetic analysis using whole-exome and -genome sequencing in 128 trios with CFM. Two novel MYT1 mutations were identified in two participants. Sanger sequencing was used to confirm these mutations.
CONCLUSION
We identified two additional individuals with CFM who carry rare variants in MYT1, further supporting the presumptive role of this gene in the CFM spectrum.

Identifiants

pubmed: 32871052
doi: 10.1002/mgg3.1401
pmc: PMC7549594
doi:

Substances chimiques

DNA-Binding Proteins 0
MYT1 protein, human 0
Transcription Factors 0

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1401

Subventions

Organisme : NIDCR NIH HHS
ID : RC1 DE020270
Pays : United States
Organisme : NIDCD NIH HHS
ID : R00 DC011282
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE022438
Pays : United States

Informations de copyright

© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Références

Dev Dyn. 2004 Apr;229(4):907-14
pubmed: 15042714
Arch Otolaryngol Head Neck Surg. 2007 Oct;133(10):997-1001
pubmed: 17938322
J Med Genet. 2014 Oct;51(10):635-45
pubmed: 25118188
Mol Genet Genomic Med. 2019 Oct;7(10):e00959
pubmed: 31469246
Nucleic Acids Res. 2012 May;40(9):3990-4001
pubmed: 22223247
Mech Dev. 2007 Nov-Dec;124(11-12):898-910
pubmed: 17928203
Eur J Hum Genet. 2017 Sep;25(9):1083-1086
pubmed: 28612832
Neuroscience. 2005;136(1):171-9
pubmed: 16198487
Clin Dysmorphol. 2009 Apr;18(2):67-77
pubmed: 19305190
Am J Med Genet. 1983 Jun;15(2):233-53
pubmed: 6881197
Transgenic Res. 2011 Aug;20(4):951-61
pubmed: 21267777
J Med Genet. 2016 Nov;53(11):752-760
pubmed: 27358179
Cell Rep. 2016 Oct 4;17(2):469-483
pubmed: 27705795
Mol Genet Genomic Med. 2020 Oct;8(10):e1401
pubmed: 32871052

Auteurs

Daniela V Luquetti (DV)

University of Washington School of Medicine, Seattle, WA, USA.
Seattle Children's Research Institute, Seattle, WA, USA.

Carrie L Heike (CL)

University of Washington School of Medicine, Seattle, WA, USA.
Seattle Children's Research Institute, Seattle, WA, USA.

Ignacio Zarante (I)

Human Genomics Institute, Pontificia Universidad Javeriana, Bogotá, Colombia.
Hospital Universitario San Ignacio, Bogotá, Colombia.

Andrew E Timms (AE)

Seattle Children's Research Institute, Seattle, WA, USA.

Jonas Gustafson (J)

Seattle Children's Research Institute, Seattle, WA, USA.

Harry Pachajoa (H)

Universidad Icesi, Cali, Colombia.

Gloria L Porras-Hurtado (GL)

Clinica Comfamiliar Risaralda, Pereira, Colombia.

Paola Ayala-Ramirez (P)

Human Genomics Institute, Pontificia Universidad Javeriana, Bogotá, Colombia.

Milagros M Duenas-Roque (MM)

Hospital Edgardo Rebagliati Martins, Lima, Peru.

Natalia Jimenez (N)

Pontificia Universidad Javeriana, Cali, Colombia.

Lina M Ibanez (LM)

Pontificia Universidad Javeriana, Cali, Colombia.

Paula Hurtado-Villa (P)

Pontificia Universidad Javeriana, Cali, Colombia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH